THX Pharma (STU:3VG) Retained Earnings: €-5.31 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:3VG THX Pharma STU:3VG
37 GF Score
Price €3.65
! 2 Warning Signs
View Full Analysis

What is THX Pharma Retained Earnings?

THX Pharma STU:3VG -0.41% 37 Retained Earnings is €-5.31 Mil as of Dec. 2025. GuruFocus rates STU:3VG with a GF Score™ of 37/100. The stock has 2 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. THX Pharma's retained earnings for the quarter that ended in Dec. 2025 was €-5.31 Mil.

THX Pharma's quarterly retained earnings increased from Dec. 2024 (€-4.57 Mil) to Jun. 2025 (€-3.38 Mil) but then declined from Jun. 2025 (€-3.38 Mil) to Dec. 2025 (€-5.31 Mil).

THX Pharma's annual retained earnings increased from Dec. 2023 (€-6.83 Mil) to Dec. 2024 (€-4.57 Mil) but then declined from Dec. 2024 (€-4.57 Mil) to Dec. 2025 (€-5.31 Mil).


THX Pharma  (STU:3VG) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


THX Pharma Retained Earnings Historical Data

* Premium members only.

The historical data trend for THX Pharma's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

THX Pharma Retained Earnings Chart

THX Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.15 -6.57 -6.83 -4.57 -5.31

THX Pharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.83 -2.71 -4.57 -3.38 -5.31
STU:3VG
37GF Score
THX Pharma STU:3VG
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

THX Pharma Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of €-5.31 Mil mean?
THX Pharma (STU:3VG) has a Retained Earnings of €-5.31 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on THX Pharma and its competitors.
Is THX Pharma's Retained Earnings too high?
THX Pharma's current Retained Earnings is €-5.31 Mil. Overall, THX Pharma has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does THX Pharma's Retained Earnings compare to VRTX and REGN?
THX Pharma's Retained Earnings of €-5.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on THX Pharma and its competitors. THX Pharma's current Retained Earnings is €-5.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is THX Pharma stock overvalued right now?
THX Pharma (STU:3VG) has a current Retained Earnings of €-5.31 Mil. The current Retained Earnings is €-5.31 Mil. THX Pharma's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For THX Pharma (STU:3VG), the current Retained Earnings is €-5.31 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

THX Pharma Business Description

Other Exchanges ALTHX:France
Address 60 avenue Rockefeller, Pepiniere Laennec, Lyon, FRA, 69008
THX Pharma Formerly Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson's disease, THN201 for the treatment of neurocognitive disorders in Alzheimer's disease and THN101 for neuropathic pain.
37GF Score

Get the complete analysis for STU:3VG

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.65
Price